Preparation and stability testing of a hydrogel for topical analgesia.

With the commercial availability of a cream (EMLA) containing a eutectic mixture of local anaesthetics, 2.5% (w/w) lidocaine and 2.5% (w/w) prilocaine, effective topical anaesthesia of the intact skin is possible without the need for subcutaneous injections or exposure to high concentrations of local anaesthetics.

Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.

Iodine-131 radioiodinated meta-iodobenzylguanidine (131I-MIBG) is used for diagnostic scintigraphy and radionuclide therapy of neural crest-derived tumours. In higher doses (up to 80 mg), non-radioactive MIBG is now evaluated for palliation in carcinoid patients. After administration of therapeutic doses of 131I-MIBG (3.

High-performance liquid chromatographic determination of m-iodobenzylguanidine in urine of cancer patients.

An accurate, sensitive, reproducible and selective HPLC assay is presented for the quantitative determination of m-iodobenzylguanidine (MIBG) in human urine. The sample pretreatment involves a solid-phase extraction on Bakerbond SPE cyano columns. The HPLC systems consists of a muBondapak C18 column and 25 mM ammonium phosphate (pH 3.